HA
BPMC

HHLR Advisors’s Blueprint Medicines BPMC Stock Holding History

HHLR Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-635,302
Closed -$55.9M – 89
2021
Q2 		$55.9M Sell
635,302
-123,389
-16% -$11.3M 0.58% 28
2021
Q1 		$73.8M Sell
758,691
-511,838
-40% -$51.1M 0.73% 24
2020
Q4 		$142M Sell
1,270,529
-94,102
-7% -$9.92M 1.13% 19
2020
Q3 		$127M Hold
1,364,631
– – 0.96% 20
2020
Q2 		$106M Sell
1,364,631
-248,663
-15% -$16.8M 0.97% 22
2020
Q1 		$94.3M Buy
1,613,294
+108,695
+7% +$6.99M 1.27% 19
2019
Q4 		$121M Buy
1,504,599
+6,083
+0.4% +$455K 1.5% 19
2019
Q3 		$110M Hold
1,498,516
– – 1.51% 18
2019
Q2 		$141M Hold
1,498,516
– – 3.16% 12
2019
Q1 		$120M Buy
1,498,516
+67,567
+5% +$4.99M 3.34% 9
2018
Q4 		$77.1M Buy
+1,430,949
New +$87M 3.2% 9

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

HHLR Advisors's BPMC Position: Q3 2021 in Review

HHLR Advisors sold out of Blueprint Medicines (BPMC) in Q3 2021, closing a stake of 635,302 shares — an estimated $55.9M sold.

HHLR Advisors first reported a position in BPMC in Q4 2018 and held it in 11 quarters. The position peaked at $142M in Q4 2020. 288 funds tracked by Wall St. Rank hold BPMC as of Q3 2021.

  • HHLR Advisors reported no remaining Blueprint Medicines position as of Q3 2021 after selling out during the quarter.
  • HHLR Advisors sold 635,302 Blueprint Medicines shares in Q3 2021, an estimated $55.9M.
  • HHLR Advisors first reported a position in Blueprint Medicines in Q4 2018 and held it in 11 quarters.
  • HHLR Advisors's Blueprint Medicines position peaked at $142M in Q4 2020.
  • 288 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.